Roles of Lymphocyte Kv1.3-Channels in the Pathogenesis of Renal Diseases and Novel Therapeutic Implications of Targeting the Channels

Table 1

Summary of changes in peak and pulse-end currents after application of CCBs, macrolide, and HMG-CoA reductase inhibitors (statins).

Drugs		Peak current density (pA/pF)		Pulse-end current/peak current () (%)
		Before	After	Before	After
Nifedipine (100 M)	5	297 ± 3.3	196 ± 2.6^#	61.3 ± 1.8	26.2 ± 5.4^#
Benidipine (10 M)	5	384 ± 47	120 ± 15^#	53.4 ± 4.6	1.14 ± 0.21^#
Clarithromycin (100 M)	5	277 ± 4.4	89.6 ± 10^#	48.5 ± 1.4	15.8 ± 1.0^#
Pravastatin (1 mM)	5	309 ± 16	278 ± 17	52.1 ± 2.4	33.4 ± 4.2^#
Lovastatin (10 M)	5	301 ± 12	237 ± 5.0^#	55.1 ± 0.4	26.8 ± 0.7^#
Simvastatin (10 M)	5	307 ± 3.7	225 ± 28^#	47.3 ± 3.9	12.1 ± 2.2^#

Data modified from [18, 20, 21].
Values are means ± SEM.
CCBs: calcium channel blockers.
< 0.05 versus before drug application.